Fig. 3.
Mutant RPE65s formed high molecular weight complexes (HMC) via disulfide bonds. ARPE-19 cells expressing WT or the indicated mutant RPE65 were treated with inhibitor of ubiquitin-activating enzyme (UBEI-41) and subjected to immunoblot analysis in the presence or absence of reducing reagent (DTT).